Qomel Co. announced on February 1, 2026, that its subsidiary, Qomel Factory in Sudair Industrial City, has obtained Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority for packaging human pharmaceutical products. The company has also commenced trial operations as a step toward full commercial operations. Positive financial impact is expected in the first half of 2026 after completing commercial operation phases. This achievement supports Qomel's strategy to enhance manufacturing capabilities, localize pharmaceutical production, and strengthen supply chains in alignment with Saudi Vision 2030.

Original announcement:

Important Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.